March 24, 2020
Company: Chiome Bioscience Inc.
Representative: Shigeru Kobayashi, President & CEO
(Code: 4583, Tokyo Stock Exchange Mothers)
Inquiries: Arihiko Bijohira, Executive Director & CFO
Phone: +81-3-6383-3746

Submission of the application for a Phase I clinical trial of CBA-1205

Chiome Bioscience Inc., announced today that it has submitted an initial application for a Phase I clinical trial on CBA-1205 to the Pharmaceuticals and Medical Devices Agency (PMDA) on March 24th, 2020.

CBA-1205 is a novel afucosylated humanized antibody targeting cell surface antigen DLK-1 which expresses on several types of solid cancer, such as liver cancer and lung cancer. There has been no development targeting DLK-1 and it is the first-in-class target. Also, this trial is the first-in-human Phase I study and is scheduled to start after the PMDA's 30-day review period and the approval from the Institutional Review Board of clinical sites.

There is no impact on the financial performance in the fiscal period ending December 31, 2020.

＜About CBA-1205＞

CBA-1205 is a novel glycoengineered humanized antibody targeting cell surface antigen "DLK-1 (Delta-like 1homolog)" which expresses on hapatocellular carcinoma and other solid cancers. CBA-1205 exhibits potent and specific anti-tumor activity in various DLK-1 expressing cancer models. DLK-1 is known to control the proliferation and differentiation of stem cells, progenitor cells, and other immature cells, and CBA-1205 is expected to offer a new therapeutic option for the treatment of DLK-1 expressing cancer such as hepatocellular carcinoma.

＜About 30-day review＞

The initial application of clinical study should be submitted at least 30 days before the contract with a clinical site is finalized. This rule is called the 30-day review.